Significance of syncope in patients with Alzheimer's disease treated with cholinesterase inhibitors

Europace

Volumn 5, Issue 4, 2003, Pages 429-431

  Bordier, Philippe ^a   Garrigue, S ^a   Barold, S S ^b   Bressolles, N ^a   Lanusse, S ^a   Clementy J ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b TAMPA GENERAL HOSPITAL   (United States)

Author keywords

Alzheimer's disease; Bradycardia; Cholinesterase inhibitors

Indexed keywords

CHOLINESTERASE INHIBITOR; CLOMIPRAMINE; DOMPERIDONE; DONEPEZIL; LISINOPRIL; NICARDIPINE; OXAZEPAM; PROPAFENONE; PROPRANOLOL; TIMOLOL; TRIMETAZIDINE;

AGED; ALZHEIMER DISEASE; ARTICLE; ARTIFICIAL HEART PACEMAKER; BRADYCARDIA; CASE REPORT; CLINICAL FEATURE; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; FEMALE; HUMAN; HYPERTENSION; MALE; MEDICAL DECISION MAKING; MEDICAL DOCUMENTATION; PRIORITY JOURNAL; SYNCOPE; TREATMENT INDICATION; VERTIGO;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRADYCARDIA; CHOLINESTERASE INHIBITORS; FEMALE; HUMANS; INDANS; MALE; PACEMAKER, ARTIFICIAL; PIPERIDINES; SYNCOPE;

EID: 0242319811     PISSN: 10995129     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1099-5129(03)00080-1     Document Type: Article

References (16)

1. Fox PJ, Kohatsu N, Max W, Arnsberger P. Estimating the costs of caring for people with Alzheimer disease in California: 2000-2040. J Public Health Policy 2001; 22: 88-97.
2. Fratiglioni L, Launer LJ, Andersen K, et al. Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54: S10-S15.
3. Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54: S4-S9.
4. Wolfson C, Wolfson DB, Asgharian M, et al. Clinical Progression of Dementia Study Group. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med 2001; 344: 1111-6.
5. Grutzendler J, Morris JC. Cholinesterase inhibitors for Alzheimer's disease. Drugs 2001; 61: 41-52.
6. Shintani EY, Uchida KM. Donepezil: an anticholinesterase inhibitor for Alzheimer's disease. Am J Health Syst Pharm 1997; 54: 2805-10.
7. Calvo-Romero JM , Ramos-Salado JL. Symptomatic sinus bradycardia associated with donepezil. (in Spanish) Rev Neurol 1999; 28: 1070-2.
8. Shepherd G, Klein-Schwartz W, Edwards R. Donepezil overdose: a tenfold dosing error. Ann Pharmacother 1999; 33: 812-5.
9. Mant T, Troetel WM, Imbimbo BP. Maximum tolerated dose and pharmacodynamics of eptastigmine in elderly healthy volunteers. J Clin Pharmacol 1998; 38: 610-7.
10. Greenberg SM, Tennis MK, Brown LB, et al. Donepezil therapy in clinical practice: a randomized crossover study. Arch Neurol 2000; 57: 94-9.
11. Homma A, Takeda M, Imai Y, et al. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group. Demerit Geriatr Cogn Disord 2000; 11: 299-313.
12. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in Alzheimer's disease. The Galantamine USA-10 Study Group. Neurology 2000; 54: 2269-76.
13. Blass JP, Cyrus PA, Bieber F, Gulanski B. Randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety tolerability of metrifonate in patients with probable Alzheimer disease. The Metrifonate Study Group. Alzheimer Dis Assoc Disord 2000; 14: 39-45.
14. Savci V, Gurun MS, Cavun S, Ulus IH. Cardiovascular effects of centrally injected tetrahydroaminoacridine in conscious normotensive rats. Eur J Pharmacol 1998; 346: 35-41.
15. Rees SA, Curtis MJ. Tacrine inhibits ventricular fibrillation induced by ischaemia and reperfusion and widens QT interval in rat. Cardiovasc Res 1993; 27: 453-8.
16. Fitzpatrick AP, Lee RJ, Epstein LM, Lesh MD, Eisenberg S, Sheinman MM. Effect of patient characteristics on the yield of prolonged baseline head-up tilt testing and the additional yield of drug provocation. Heart 1996; 76: 406-11.